Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E
Status:
Recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
We propose to conduct a randomized clinical trial, investigating the safety and efficacy of
brolucizumab for treatment of nAMD patients with CNV. We plan to specifically target those
who are not responding to standard Treat and Extend (T&E) treatment. We will conduct a
randomized study with 2 arms, one with the new drug (brolocizumab) and novel treatment
protocol versus a second arm using the current gold standard of aflibercept and the T&E
protocol